Global Tapentadol Market Expands within Rising Incidence Chronic Diseases

San Francisco, California, November 13th, 2018: The demand within the global market for tapentadol has been rising on account of the rising incidence of chronic diseases that result in severe musculoskeletal pain. Tapentadol belongs to a certain class of narcotic analgesic drugs that can help in relieving pain in the human body. The demand for tapentadol has been rising across the world because a number of medical practitioners have begun recommending tapentadol to relieve patients of chronic pain. Tapentadol does not have any significant side effects, and this factor further encourages people towards the use of this analgesic. A report added by TMR Research on the global market for tapentadol market creates a framework to understand the key dynamics of this market. The title of the report is “Tapentadol Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025”.

Get Sample Copy of this Report @

The rising incidence of diabetes and other chronic diseases that can result in frequent musculoskeletal pain has propelled demand within the global market for tapentadol. However, the use of tapentadol is not recommended for patients with brain tumour or head injuries as it could cause further damage in the brain. This factor, coupled with the ill-effects of tapentadol on asthma patients, could hamper the growth of the global market for tapentaol.

On the basis of geography, the research and development initiatives to test the effect of tapentadol on sufferers of various diseases in the US and Canada has led to the growth of the market for tapentadol in North America.

Read Comprehensive Overview of Report @

Some of the key players in the global market for tapentadol are Aristo Pharmaceuticals Pvt. Ltd., Tirupati Medicare Ltd, and Cadila Pharmaceuticals Ltd.

Tapentadol Market: Chronic Musculoskeletal Pain Cases on the Rise

San Francisco, California, July 17, 2017 :“Tapentadol Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025” is a deep and descriptive investigation of what constitute as the positive and negative aspects of influence for tapentadol, in terms of sales, revenue generated, core regions for analysis, and future scope. The drug was approved by the USFDA in 2008 and has since found an optimistic scope of use as a moderate opioid with an analgesic efficacy nearly similar to oxycodone, while imparting a much smaller list of side effects. One of the key advantages of tapentadol is that it is not a pro-drug and therefore does not have to be metabolized in order to have full effect.

One of the primary drivers impacting the global tapentadol market is the growing number of patients suffering from chronic diseases and the related musculoskeletal pains. Opioids are considered to be one of the top treatments for chronic pains, and tapentadol fills a gap in the pharmaceutical industry for people who have more severe reactions to older opioids, or are unable to fully metabolize them to gain their advantages. Tapentadol is also known to show lower side effects than other members in its group, thereby receiving a greater preference. The efficacy of tapentadol is gauged to be somewhere between that of tramadol and morphine.

However, the global tapentadol market is currently being restrained by its own list of adverse side effects. The drug is linked to loss of physical as well as cognitive abilities if used extensively. It is strongly advised by medical practitioners to avoid handling heavy machinery while on the opioid. Other side effects include CNS sedation, dizziness, constipation, and nausea, and many patients have been recorded to show most of these. Prolonged consumption of tapentadol is also being linked to the elevated risk of seizures, which makes them a risky opioid to be administered to patients suffering from epilepsy.

From a regional perspective, North America is expected to continue leading the global tapentadol market, as it has done over the recent years. The region is known for a heavy presence of the leading players in the pharmaceutical industry, as well as pushing for further research and development through government-granted as well as private investments and incentive schemes. Europe is showing a similar growth pattern, owing to the significantly higher population of geriatric patients in the region.

The leading players in the global tapentadol market so far, have included Johnson & Johnson Pharmaceutical Research & Development, L.L.C., IPCA Laboratories Ltd., Lupin Laboratories Ltd., Ranbaxy Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Cadila Pharmaceuticals Ltd., Tirupati Medicare Ltd, and Manus Aktteva Biopharma LLP.